Partnering News

01.04.2017

Spark Therapeutics Announces $15 Million Milestone Payment from Pfizer for Progress in Hemophilia B Gene Therapy Program

12.21.2016

BioInvent announces Cancer Immunotherapy Research Collaboration and License Agreement with Pfizer and issues new shares to Pfizer

12.21.2016

Circle Pharma, developer of macrocyclic peptide therapeutics, announces Series A financing and appoints Walter H. Moos, Ph.D., to its board

12.20.2016

Draper to Build Preclinical Microphysiological Systems with Pfizer to Help Predict Clinical Outcomes

12.13.2016

Pediatric Open Innovation Challenge Grantees Awarded $50,000 by the Institute for Pediatric Innovation and Pfizer

12.13.2016

Ab Initio Announces Strategic Collaboration with Pfizer to Discover GPCR Activating Antibodies

12.12.2016

Pioneers in Oncolytic Virus and Gene Therapy Fields Announce Formation of IGNITE Immunotherapy Inc., a Company Focused on Oncolytic Cancer Vaccine Discovery and Development

12.09.2016

Akili and Pfizer Present Positive Data from Digital Biomarker Study to Detect Subtle Cognitive Changes in Healthy Subjects at Risk of Developing Alzheimer’s Disease

12.03.2016

Spark Therapeutics and Pfizer Present Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting

11.03.2016

Spark Therapeutics and Pfizer Announce Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Sustained Therapeutic Levels of Factor IX Activity

10.19.2016

DILIsym Services, Inc. Utilizes Flagship Technology to Evaluate Prospective NAFLD Treatments in Collaboration with Pfizer Inc.

09.28.2016

iTeos Announces Initiation of Phase 1 Clinical Trial of IDO1 inhibitor